GSK stops Phase II feladilimab trial

15 April 2021

UK pharma major GlaxoSmithKline (LSE: GSK) today announced that, following a recommendation by the Independent Data Monitoring Committee, it has taken the decision to stop enrolling patients in the Phase II INDUCE-3 trial, including discontinuing treatment with feladilimab.

The INDUCE-3 study is investigating feladilimab in combination with Merck & Co’s (NYSE: MRK) Keytruda (pembrolizumab) versus placebo in combination with pembrolizumab in patients with PD-L1 positive recurrent locally advanced or metastatic head and neck squamous cell carcinoma.

GSK has also made the decision to stop the INDUCE-4 Phase II trial, a study investigating feladilimab versus placebo in combination with pembrolizumab and chemotherapy.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK